Phase II Study of Camrelizumab with Chemotherapy Before Surgery for Esophageal Squamous Cell Cancer to Preserve Organs

What this Trial Is About

Researchers are evaluating the effectiveness, safety, and feasibility of preserving organs using camrelizumab combined with chemotherapy in patients diagnosed with resectable esophageal squamous carcinoma. This multicenter phase II clinical trial focuses on patients confirmed to have esophageal squamous carcinoma that can be surgically removed. The goal is to explore treatment options that may improve outcomes and organ preservation in this patient group. Participants will receive three cycles of neoadjuvant therapy including camrelizumab 200 mg per dose intravenously every 3 weeks, nab-paclitaxel 260 mgm2 intravenously every 3 weeks, and cisplatin 75 mgm2 intravenously every 3 weeks. Patients opting for organ preservation may enter a watchful waiting group receiving radiotherapy 50.4 Gy in 28 doses followed by camrelizumab maintenance therapy for 4 to 12 weeks after radiotherapy, with a total treatment duration of up to one year of camrelizumab. Throughout the study, participants will undergo evaluations including tumor measurements and organ function tests to assess treatment response and safety. Researchers will monitor outcomes such as event-free survival over about two years, clinical and pathological remission rates, progression-free survival, overall survival in organ preservation cases, and adverse events. Participants will be followed closely during treatment and for approximately two years to gather comprehensive data on treatment effects and safety.

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer